Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
xGvMcR2GCwtGyhK0
